BIOARCTICAB financials
BIOARCTICAB
549300Y0OI2WVUNHLC33 ISIN: SE0010323311 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 257.4M | SEK 616.0M |
| Cost of sales | SEK 27.0M | SEK 15.0M |
| Gross profit | SEK 230.4M | SEK 601.0M |
| Administrative expenses | SEK 93.4M | SEK 128.5M |
| Operating expenses | SEK 458.9M | SEK 348.4M |
| Operating profit (EBIT) | -SEK 228.5M | SEK 252.6M |
| Finance costs | SEK 1.8M | SEK 10.4M |
| Profit before tax | -SEK 189.5M | SEK 276.5M |
| Income tax expense | -SEK 12.4M | SEK 47.2M |
| Profit for the year | -SEK 228.5M | SEK 252.6M |
| — attributable to owners | -SEK 177.1M | SEK 229.2M |
| Total comprehensive income | -SEK 177.0M | SEK 229.2M |
| Cash flow statement | ||
| Cash generated from operations | -SEK 316.3M | SEK 309.7M |
| Income taxes paid | -SEK 520.0K | SEK 156.0K |
| Net cash from investing activities | SEK 205.6M | -SEK 507.5M |
| Purchase of PP&E (capex) | SEK 26.6M | SEK 7.4M |
| Net cash from financing activities | SEK 5.7M | SEK 14.1M |
| Dividends paid | -SEK 6.0M | -SEK 15.0M |
| Lease liability payments | SEK 329.0K | SEK 917.0K |
| Net change in cash | -SEK 105.0M | -SEK 183.73B |
| Balance sheet | ||
| Total assets | SEK 1.11B | SEK 1.19B |
| Non-current assets | SEK 101.0M | SEK 33.3M |
| Property, plant & equipment | SEK 39.5M | SEK 23.5M |
| Right-of-use assets | SEK 57.2M | SEK 7.6M |
| Current assets | SEK 1.01B | SEK 1.15B |
| Trade & other receivables | SEK 71.2M | SEK 223.0K |
| Cash & equivalents | SEK 512.9M | SEK 611.6M |
| Total equity | SEK 894.9M | SEK 1.05B |
| — attributable to owners | SEK 894.9M | SEK 1.05B |
| Non-current liabilities | SEK 41.1M | SEK 14.5M |
| Lease liabilities (non-current) | SEK 41.1M | SEK 2.2M |
| Current liabilities | SEK 175.7M | SEK 125.0M |
| Lease liabilities (current) | SEK 13.1M | SEK 2.8M |
| Trade & other payables | SEK 50.5M | SEK 29.9M |
| Deferred tax liabilities | SEK 0 | SEK 12.4M |
| Derived metrics | ||
| Operating margin | -88.8% | 41.0% |
| Net margin | -88.8% | 41.0% |
| Return on equity | -25.5% | 24.1% |
| Other reported items | ||
| Accruals and Deferred Income Including Contract Liabilities | SEK 68.3M | SEK 48.8M |
| Adjustments For Decrease Increase In Other Operating Receivables | -SEK 105.2M | -SEK 12.0M |
| Adjustments For Increase Decrease In Other Operating Payables | SEK 42.7M | SEK 25.1M |
| Basic Earnings Loss Per Share From Continuing Operations | SEK -200000.00 | SEK 260000.00 |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 253.8M | SEK 296.5M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 177.0M | SEK 229.2M |
| Current Tax Liabilities Current | SEK 33.6M | SEK 33.8M |
| Deferred Tax Assets | SEK 957.0K | SEK 566.0K |
| Diluted Earnings Loss Per Share From Continuing Operations | SEK -200000.00 | SEK 259000.00 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 6.4M | -SEK 10.1M |
| Equity and Liabilities | SEK 1.11B | SEK 1.19B |
| Finance Income | SEK 40.8M | SEK 34.2M |
| Increase Decrease Through Other Contributions By Owners | SEK 42.0K | -SEK 29.0M |
| Increase Decrease Through Sharebased Payment Transactions | SEK 19.3M | SEK 16.1M |
| Interest Paid Classified As Operating Activities | -SEK 1.8M | -SEK 379.0K |
| Interest Received Classified As Operating Activities | SEK 34.5M | SEK 34.2M |
| Issue of Equity | SEK 6.1M | SEK 15.0M |
| Issued Capital | SEK 1.8M | SEK 1.8M |
| Miscellaneous Other Operating Expense | SEK 2.6M | SEK 8.1M |
| Other Adjustments For Noncash Items | -SEK 57.4M | SEK 9.9M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 42.0K | -SEK 26.0K |
| Other Current Liabilities | SEK 10.1M | SEK 9.7M |
| Other Current Receivables | SEK 35.6M | SEK 6.9M |
| Other Inflows Outflows of Cash Classified As Investing Activities | SEK 232.3M | -SEK 500.0M |
| Other Noncurrent Financial Assets | SEK 3.4M | SEK 1.6M |
| Other Operating Income Expense | SEK 3.7M | SEK 4.1M |
| Other Reserves | SEK 958.0K | SEK 958.0K |
| Prepayments and Accrued Income Including Contract Assets | SEK 124.9M | SEK 34.1M |
| Profit Loss From Continuing Operations | -SEK 177.1M | SEK 229.2M |
| Research and Development Expense | SEK 311.1M | SEK 172.1M |
| Retained Earnings | SEK 305.1M | SEK 462.9M |
| Sales and Marketing Expense | SEK 55.5M | SEK 43.7M |
| Share Premium | SEK 587.1M | SEK 581.0M |
| Shortterm Investments Classified As Cash Equivalents | SEK 266.0M | SEK 500.0M |
Every line item above is a fact tagged in BIOARCTICAB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.